Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study

被引:25
|
作者
Velentzis, Louiza S. [1 ]
Banks, Emily [2 ]
Sitas, Freddy [3 ]
Salagame, Usha [1 ]
Tan, Eng Hooi [4 ]
Canfell, Karen [1 ,3 ,5 ]
机构
[1] NSW Canc Council, Canc Res Div, Sydney, NSW, Australia
[2] Australian Natl Univ, Res Sch Populat Hlth, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia
[3] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[4] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[5] Univ New S Wales, Lowy Canc Res Ctr, Sydney, NSW, Australia
来源
PLOS ONE | 2016年 / 11卷 / 03期
基金
英国医学研究理事会;
关键词
HEALTH; TRENDS;
D O I
10.1371/journal.pone.0146494
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Menopausal Hormone Therapy (MHT) use in Australia fell by 55% from 2001 to 2005, following the release of large-scale findings on its risks and benefits. Comprehensive national data, including information on overall prevalence of MHT use as well as information on duration of use in Australia have not been reported since the 2004-5 National Health Survey, when 11% of women aged 45+ years were estimated to be current MHT users. No national data are available on prevalence of use of "bioidentical" hormone therapy (BHT). The objective of this study was to determine recent prevalence of MHT and BHT use. A cross-sectional, national, age-stratified, population survey was conducted in 2013. Eligible women, aged 50-69 years, resident in Australia were randomly sampled in 5-year age groups from the Medicare enrolment database (Australia's universal health scheme). The response rate was 22% based on return of completed questionnaires, and analyses were restricted to 4,389 women within the specified age range. The estimated population-weighted prevalence of current use of MHT was 13% (95% CI 12-14), which was broadly similar to the previously reported national figures in 2004-5, suggesting that the use of MHT in Australia has largely stabilised over the past decade. A total of 39% and 20% of current-users with an intact uterus reported use of oestrogen-progestagen MHT and oestrogen-only MHT, respectively, whereas 77% of hysterectomised current-users used oestrogen-only MHT. Almost three-quarters of current-users [population-weighted prevalence 9% (95% CI 8-10)] had used MHT for >= 5 years. In regard to BHT, estimated population-weighted prevalence of ever use was 6% (95% CI 6-7) and 2% (95% CI 2-3) for current use. The population-weighted prevalence of MHT and BHT combined, in current users in their fifties and sixties was 15% (95% CI 14-16). These data provide a recent national "snapshot" of Australian women's use of both conventional MHT and of BHT.
引用
收藏
页数:12
相关论文
共 27 条
  • [1] Menopausal hormone therapy: Characterising users in an Australian national cross-sectional study
    Velentzis, Louiza S.
    Egger, Sam
    Banks, Emily
    Canfell, Karen
    PLOS ONE, 2021, 16 (08):
  • [2] Knee osteoarthritis and menopausal hormone therapy in postmenopausal women: a nationwide cross-sectional study
    Jung, Jae Hyun
    Bang, Cho Hee
    Song, Gwan Gyu
    Kim, Cholhee
    Kim, Jae-Hoon
    Choi, Sung Jae
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (06): : 598 - 602
  • [3] Vaginal microbiota, menopause, and the use of menopausal hormone therapy: a cross-sectional, pilot study in Chinese women
    Lan, Yibing
    Jin, Bihui
    Zhang, Yue
    Huang, Yizhou
    Luo, Zhou
    Su, Chang
    Li, Jingjing
    Ma, Linjuan
    Zhou, Jianhong
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (11): : 1014 - 1023
  • [4] Prevalence of menopausal symptoms and attitudes towards menopausal hormone therapy in women aged 40-60 years: a cross-sectional study
    Lu, Jie
    Li, Kangfen
    Zheng, Xinlie
    Liu, Ran
    Chen, Min
    Xian, Jingyun
    Tu, Suhua
    Xie, Lingling
    BMC WOMENS HEALTH, 2023, 23 (01)
  • [5] Menopausal symptoms and utilization of menopausal hormone therapy among women aged 40-60 years in Addis Ababa, Ethiopia: a cross-sectional study
    Asfaw, Tewodros Getahun
    Gebreyohannes, Rahel Demissew
    Tesfaye, Milcah Temesgen
    BMC WOMENS HEALTH, 2024, 24 (01)
  • [6] Hormone therapy use in the Canadian Longitudinal Study on Aging: a cross-sectional analysis
    Costanian, Christy
    Edgell, Heather
    Ardern, Chris I.
    Tamim, Hala
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (01): : 46 - 53
  • [7] Swedish physicians' knowledge of and prescribing practices for menopausal hormone therapy: A nationwide cross-sectional survey
    Eriksson, Rebecca Gotze
    Skalkidou, Alkistis
    Cruz, Natalia
    Hirschberg, Angelica Linden
    Iliadis, Stavros I.
    MATURITAS, 2025, 197
  • [8] Effects of ovarian reserve and hormone therapy on hearing in premenopausal and postmenopausal women: A cross-sectional study
    Zhang, Jingfei
    Zhang, Tingyue
    Yu, Lisheng
    Ruan, Qianying
    Yin, Lingxue
    Liu, Dong
    Zhang, Haicheng
    Bai, Wenpei
    Ren, Zhenghong
    MATURITAS, 2018, 111 : 77 - 81
  • [9] Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age
    Li, Christopher I.
    Daling, Janet R.
    Haugen, Kara L.
    Tang, Mei Tzu Chen
    Porter, Peggy L.
    Malone, Kathleen E.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 481 - 489
  • [10] Use and discontinued use of menopausal hormone therapy by healthy women in Norway: the Hordaland Women's Cohort study
    Gjelsvik, Bjorn Espen
    Straand, Jorund
    Hunskaar, Steinar
    Dalen, Ingvild
    Rosvold, Elin O.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (05): : 459 - 468